Business Wire

IFF and Master Perfumer Carlos Benaim Celebrate 50 Years Together

Jaa

Regulatory News:

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171114006629/en/

Carlos Benaim (Photo: Business Wire)

Carlos Benaim (Photo: Business Wire)

International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, is honoring the 50th anniversary of its Master Perfumer, Carlos Benaim with a series of celebrations throughout the next year.

“It is impossible to overstate the importance of Carlos’ contributions not only to IFF, but to the whole industry,” said Andreas Fibig, IFF Chairman and CEO. “The history of perfumery over the last 50 years has been shaped in many ways by the hand of Carlos Benaim. I consider it our greatest fortune that he chose to make his career with IFF.”

Born in Morocco and the son of a pharmacist, Mr. Benaim was intrigued by the botanicals and essential oils used in his father’s business. He studied chemistry at the University of Toulouse and Ecole Nationale Superíeure de Chimie de Toulouse in France. After answering an ad for a position at IFF in 1967, his year of training culminated with an apprenticeship with the legendary perfumer Ernest Shiftan – the “father of perfumery” at IFF – and later, trained with Bernard Chant. In the ensuing years, Mr. Benaim created hundreds of iconic fragrances for men and women, nine of which won the industry’s highest honor – the Fragrance Foundation Award. In 2002, he received a Lifetime Achievement Award from the American Society of Perfumers and in 2014, he was recognized by the Fragrance Foundation with a Perfumer of the Year Lifetime Achievement Award. In 2013, he was named IFF’s first-ever Master Perfumer in recognition of his creativity, mastery of his art, market success, and exceptional customer relationships.

Nicolas Mirzayantz, Group President, Fragrances, said, “Carlos, a true gentleman in every sense of the word, is also a genius of perfumery who has selflessly shared his knowledge by coaching, mentoring, and inspiring countless perfumers over the years. A master of natural ingredients, Carlos is at the cutting edge of his creativity and innovation and I’m excited, as always, to see what successful and iconic fragrances he will create for us – and our customers – in the future. His passion for his art, the industry, and our customers is unparalleled. Beyond the extraordinary pleasure of having Carlos as my colleague, I am also proud to call him a dear and lifelong friend.”

Mr. Benaim’s creations and co-creations include Polo Green and Polo Blue by Ralph Lauren; Euphoria by Calvin Klein; Eternity for Men by Calvin Klein; Herrera for Men by Carolina Herrera; Solo by Loewe; White Diamonds by Elizabeth Taylor; Fierce by Abercrombie & Fitch; Jasmin Noir by Bulgari; Very Irresistible Givenchy by Givenchy; Prada Amber by Prada; Armani Code for Women by Giorgio Armani; Flowerbomb, Spicebomb, and Antidote by Viktor & Rolf; Eau De Magnolia by Carlos Benaim for Frederic Malle; and many others.

Mr. Benaim reflected, “I want to talk not about what I did for IFF, but what IFF did for me. IFF trained me to be a perfumer, opened the doors of the major customers worldwide, and helped at every step along my path toward a successful international career. IFF gave me creative freedom. Fifty years later, with all the clarity of hindsight, I know that finding IFF was one of the luckiest accidents of my life.”

Meet IFF

International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers taste, smell, or feel in fine fragrances and beauty, detergents and household goods, as well as beloved foods and beverages. Our 7,400 team members globally take advantage of leading consumer insights, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products. Learn more at www.iff.com, Twitter , Facebook, Instagram, and LinkedIn.

Contact information

International Flavors & Fragrances Inc.
Michael DeVeau, 212-708-7164
VP, Corporate Strategy, Investor Relations & Communications
Michael.DeVeau@iff.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Beko Becomes the Naming Partner of Fenerbahçe Men's Basketball Team19.12.2018 13:00Tiedote

To forge its support to sports and healthy living, Beko is now the naming partner of Fenerbahçe Men's Basketball Team. Beko has been supporting basketball teams in Turkish Basketball League and also sponsored the European Basketball Championship for many years and now it takes on the naming partnership of Fenerbahçe Men's Basketball Team for 2.5 years. This new naming partnership agreement focuses on “Eat Like A Pro” – an initiative launched by Beko to fight childhood obesity. Through this collaboration, Beko plans to expand the scope of the campaign to promote healthy eating habits among children by advertising their hero basketball players as role models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005026/en/ Beko Becomes Naming Partner of Fenerbahce Men’s Basketball Team (Photo: Business Wire) Beko, a leading white goods brand providing products and services in more than 130 countries, returns to investing in bas

Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 11:00Tiedote

The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease

Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 11:00Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil

SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 10:50Tiedote

SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING

Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 10:39Tiedote

Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme